Patients are becoming more aware of innovative treatments for both diabetes and obesity, boosting demand
Material sold research-use-only carries unverified identity and purity
Phase 2 obesity trial (NEJM, 2023), retatrutide produced a mean body-weight reduction of up to 24.2% at 48 weeks in the highest-dose cohort, following a 2 mg starting dose escalated every four weeks to 12 mg weekly [1][2]
US Wegovy scripts in September and October 2025 were the highest on record, driven in large part by former compound users switching to the branded product
This is the same core mechanism used to extend tirzepatide and semaglutide beyond the typical GLP-1 peptide half-life of minutes to hours
Eli Lillys retatrutide, which is in clinical trials, may help users shed up to 24% of their body weight after 48 weeks